logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Pfizer To Acquire Biohaven Pharmaceuticals

May 10, 2022•over 3 years ago

Acquiring Company

Pfizer

Acquired Company

Biohaven

New Yorkpharmaceuticals

Description

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.

Company Information

Company

Pfizer

Location

66 Hudson Blvd E

New York, New York, United States

About

Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. Seagen is recognized for its advancements in cancer care and plays a significant role in the oncology market. Its dedication to research and development underpins its success in the competitive biotech landscape.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed